Drugline is a fortnightly electronic drug bulletin for health professionals.


Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

New Contraindications for Glaucoma Medication

Drugline Volume 385

New contraindications have been added to the product information of Ganfort® (bimatoprost + timolol). It is now advised that these eye drops not be used in patients with sino-atrial nodal block or second or…

Read more

Ceftazidime with Avibactam

Drugline Volume 384

Zavicefta® is a new injectable cephalosporin formulation available in Australia. This product combines the broad-spectrum antibiotic, ceftazidime with the β-lactamase inhibitor, avibactam. Ceftazidime is one of a limited range of antibiotics with antipseudomonal activity….

Read more

Teduglutide for Short Bowel Syndrome

Drugline Volume 383

Teduglutide is a glucagon-like peptide (GLP) analogue recently registered in Australia for the treatment of short bowel syndrome. There are a number of other GLP analogues available including dulaglutide, exenatide, and liraglutide. While these…

Read more

Neratinib for Breast Cancer

Drugline Volume 382

Neratinib is a new tyrosine kinase inhibitor for the treatment of breast cancer. It is indicated as extended adjuvant treatment of early-stage human epidermal growth factor receptor (HER) 2 -positive disease. Initiation is recommended…

Read more

Antibiotic Awareness Week

Drugline Volume 381

World Antibiotic Awareness Week runs from 18th to 24th November 2019. This annual event aims to promote awareness of antibiotic resistance and improve the use of antibiotics in order to minimise the emergence and…

Read more

Buprenorphine Depot Injections

Drugline Volume 380

Buprenorphine is now available as a depot injection for the maintenance treatment of opioid dependence. Two products are registered in Australia, Buvidal® and Sublocade®. However, only Buvidal® is currently accessible on the Pharmaceutical Benefits…

Read more
Load More